Ting Xia

Dr. Ting Xia


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
TXTing Xia
Ting Xia
ZLZhenjie Liu
Zhenjie Liu
WDWenya Ding
Wenya Ding
LDLiting Deng
Liting Deng
XNXinyang Ning
Xinyang Ning
JFJianfang Feng
Jianfang Feng
Background/Objectives: Achyranthes bidentata (AB), recognized as a food and traditional Chinese medicine, exhibits notable biological activity. Our previous study showed the hypoglycemic effect of Achyrantha bidentata polysaccharide (ABP). The properties and digestion process of polysaccharides affect their pharmacological activities. The digestion characteristics of ABP are unclear. In this study, we aimed to explore the characteristics of ABP’s simulated digestion and its prebiotic properties and hypoglycemic effects. Methods: We used simulated digestion methods to investigate the alterations in ABP levels in the process of digestion and fermentation. Animal experiments were used to compare the effects of the prebiotic properties of ABP on normal control (NC) and type 2 diabetes mellitus (T2DM) mice. Then, in order to further verify the hypoglycemic effect of ABP after fermentation (ABPF), α-glucosidase activity and glucose uptake in Caco-2 cells were examined. Results: The results showed that ABP was anti-digestive and mainly degraded by the intestinal flora. Moreover, ABP showed a stronger promoting advantage against beneficial bacteria and inhibited harmful bacteria in the T2DM mice. Compared with NC mice, after ABP treatment, T2DM mice showed a higher increase in levels of short-chain fatty acids (SCFAs). Additionally, the glucose uptake and α-glucosidase activity of Caco-2 cells were significantly decreased after treatment with ABPF. Conclusions: These results underscore the potential of ABP as a prebiotic candidate for gut health promotion and T2DM alleviation.

30 September 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
KWKexin Wang
Kexin Wang
WXWenjie Xu
Wenjie Xu
WHWen He
Wen He
MDMengze Ding
Mengze Ding
TXTing Xia
Ting Xia
XTXiaomei Tan
Xiaomei Tan

Verified
Journal Article
Open access
PDF file
JYJunpeng Yu
Junpeng Yu
PWPeng Wang
Peng Wang
ZBZishen Bei
Zishen Bei
LTLulu Tan
Lulu Tan
JWJiaxin Wang
Jiaxin Wang
JFJianfang Feng
Jianfang Feng
Oral drugs classified under Class III of the Biopharmaceutics Classification System (BCS) are defined by high aqueous solubility yet low intestinal permeability. Their restricted oral bioavailability arises not from inadequate dissolution, but is primarily governed by the intestinal permeability barrier, coupled with substantial inter-individual variability in absorption. This review adopts the intestinal permeability barrier as its core analytical framework to dissect the key determinants of oral absorption for BCS III drugs, while presenting a comparative and critical evaluation of prevailing bioavailability enhancement strategies. From perspectives including mechanism of action, achievable magnitude of enhancement, applicable physicochemical and physiological conditions, and translational feasibility, the intrinsic mechanistic limitations and applicable boundaries of distinct strategies are delineated. Finally, this paper concludes that the absorption barriers of BCS III drugs cannot be universally surmounted by a single strategy, emphasizing the significance of mechanism-guided strategy selection for the rational design of oral drug delivery systems. In doing so, it provides a foundational basis for the rational development of oral delivery systems tailored to BCS III drugs.

Verified
Journal Article
Open access
PDF file
YSyuanle shen
yuanle shen
LZLinghui Zou
Linghui Zou
YZYinggang Zeng
Yinggang Zeng
TXTing Xia
Ting Xia
ZLZhenjie Liu
Zhenjie Liu
JFJianfang Feng
Jianfang Feng
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by synovial hyperplasia and joint destruction. Previous studies have demonstrated that the alkaloids of Rushanhu (ARSHs), the dried root and stem of Zanthoxylum nitidum var. tomentosum, exhibit favorable therapeutic effects on RA, and this study aims to investigate the underlying molecular mechanisms involved. Methods: A complete Freund’s adjuvant (CFA)-induced arthritis model in male SD rats (n = 64) was used to evaluate ARSHs. Groups included control, model, methotrexate (MTX), and ARSH-treated. Therapeutic effects were assessed via arthritis index, paw swelling, and serum cytokines (IL-1β, IL-6, IL-17A). Network pharmacology identified bioactive alkaloids and core targets, validated by molecular docking. In vitro mechanisms (proliferation, apoptosis, signaling pathways) were examined in MH7A synovial cells. Results: ARSHs significantly attenuated joint inflammation and damage in CFA rats (* p < 0.01 vs. model), reducing pro-inflammatory cytokines. Fifteen alkaloids (e.g., dihydrochelerythrine, magnoflorine) and 24 targets (e.g., SRC, STAT3, MAPK3) were prioritized. Molecular docking confirmed strong binding (binding energy < −7.0 kcal/mol). In vitro, ARSHs suppressed MH7A proliferation and induced apoptosis via Bcl-2/Bax dysregulation and the inhibition of SRC/STAT3/MAPK3 phosphorylation. Conclusions: ARSHs mitigate RA pathogenesis by targeting the SRC/STAT3/MAPK3 signaling axis in synovial cells. This study provides mechanistic validation of ARSHs as multi-target phytotherapeutic agents against inflammatory arthritis.

Verified
Journal Article
Open access
PDF file
JHJielan Huang
Jielan Huang
ZLZhenjie Liu
Zhenjie Liu
BWBaolin Wang
Baolin Wang
HQHaixin Qiu
Haixin Qiu
QCQiujie Chen
Qiujie Chen
JFJianfang Feng
Jianfang Feng
Cryptotanshinone (CTS), an antiplatelet compound from Salvia miltiorrhiza, exhibits in vitro potency comparable to aspirin. This study integrated network pharmacology and metabolomics to elucidate its underlying mechanisms. An acute blood stasis model was induced in Sprague-Dawley rats using epinephrine and ice-water immersion. Animals were assigned to seven groups. Platelet aggregation was measured turbidimetrically using arachidonic acid (AA) and adenosine diphosphate (ADP) as agonists. Core targets were predicted by network pharmacology, differential metabolites were screened, and pathways were enriched using untargeted metabolomics. Integrated analysis identified shared pathways and key targets, validated by molecular docking. AA- and ADP-induced aggregation was significantly increased in model rats versus the blank group. CTS at all doses markedly inhibited aggregation in a dose-dependent manner. Network pharmacology identified 15 core targets. Metabolomics identified 51 differential metabolites enriched in seven pathways, including glycerophospholipid and butanoate metabolism. Integrated analysis revealed five common pathways: linoleic acid metabolism, arginine biosynthesis, AA metabolism, glutathione metabolism, and drug metabolism—and four key targets (CYP3A4, NOS3, PTGS2, and GSTP1). Molecular docking showed strong binding energies (<−9 kcal/mol) between CTS and these targets. CTS inhibits platelet aggregation by regulating CYP3A4, NOS3, PTGS2, and GSTP1 and intervening in five metabolic pathways, supporting its potential as an anti-platelet agent.

18 March 2026 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
ZCZhe Chen
Zhe Chen
ZLZhenye Luo
Zhenye Luo
TXTing Xia
Ting Xia
XTXiaomei Tan
Xiaomei Tan